This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
Emergent (EBS) Earnings & Revenues Miss Estimates in Q1
by Zacks Equity Research
Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.
Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod
by Kinjel Shah
Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Alnylam (ALNY) reports narrower-than-expected loss in the first quarter of 2019. Also, sales beat estimates.
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.
BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.
Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales
by Zacks Equity Research
Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.
Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study
by Zacks Equity Research
Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.
Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth
by Zacks Equity Research
Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.
Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
by Zacks Equity Research
Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).
Inovio Closes Enrollment in Brain Cancer Study Before Time
by Zacks Equity Research
Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.
Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval
by Zacks Equity Research
Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.
AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes
by Zacks Equity Research
AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.
Lilly (LLY) Signs New Immunology Deal With Private Biotech
by Zacks Equity Research
Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
Ascendis Pivotal Growth Hormone Deficiency Study Data Positive
by Zacks Equity Research
Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug
by Zacks Equity Research
FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.
AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes
by Zacks Equity Research
AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.
Biogen Stock Crashes on Termination of Alzheimer's Studies
by Zacks Equity Research
Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.
Emergent Begins Phase III Study on Anthrax Vaccine AV7909
by Zacks Equity Research
Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study
by Zacks Equity Research
Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
by Zacks Equity Research
Key highlights of the past week are regulatory and pipeline developments.
Should Value Investors Consider Sanofi (SNY) Stock Now?
by Zacks Equity Research
Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.
Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion
by Zacks Equity Research
The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.